Back to Treatments

Treatment

Tenofovir alafenamide (TAF)

1
Conditions
2
Trials
400
Participants
72%
Average Safety

Condition Evidence

Acute hepatitis B

2 trials · 400 participants

85% effectiveness · 72% safety
Tenofovir alafenamide (TAF) | DFDA